Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer

This study is investigating whether two types of PET scan imaging — one using a tracer that targets a protein called TROP2, and one using a standard glucose tracer (FDG) — can predict how well a TROP2-targeted antibody-drug conjugate (ADC) treatment will work in patients with advanced HER2-negative breast cancer. **You may be eligible if...** - You have been diagnosed with advanced or metastatic HER2-negative breast cancer - Your doctor has already planned to treat you with an anti-TROP2 ADC drug (such as sacituzumab govitecan or datopotamab deruxtecan) as part of your standard care - You are willing and able to undergo the required PET/CT scans during the study - You are 18 years of age or older **You may NOT be eligible if...** - Your medical records are incomplete or you cannot complete the required scans - You have previously been treated with an anti-TROP2 ADC - You have a known allergy to PET scan tracers or contraindications to PET/CT imaging - You are pregnant or breastfeeding - You have another active cancer Talk to your doctor to see if this trial is right for you.